Lumen Bioscience

New hope for C. difficile patients: Lumen Bioscience announces promising results for new oral treatment. In preliminary trial results, our investigational treatment LMN-201 with SOC antibiotics: - 100% of C. diff patients successfully resolved their initial infection (typically 80% in this population)   - 95% of patients had no recurrence within 28 days  - LMN-201 comes in simple oral capsules (no IV needed), and it was well-tolerated with reports of no LMN- 201-related adverse events. C. difficile infection affects nearly 500,000 Americans yearly and can be difficult to treat with current options.  Read the full release: https://lnkd.in/g8ERJG6M n…rt-repreve-trial/   Learn more by checking out the study website at https://lnkd.in/g58bV-va

We're proud to announce that Summer Radler, MS, RAC, our Senior Director and Head of Regulatory Affairs, has been invited to join the regulatory panel at the upcoming "Digital Transformation in Healthcare & Regulatory Innovation" event.   Summer brings exceptional expertise to this discussion, having most recently served as Global Regulatory Lead for a Phase 2 investigational drug at Roivant Sciences. At Sierra Oncology (acquired by GSK), she directed global regulatory submissions for OJJAARA (momelotinib), leading its progression from pivotal Phase 3 study through EU and U.S. marketing applications.   With her M.S. in regulatory affairs from Northeastern University and certifications as both a Regulatory Affairs Professional (RAC) and Quality Auditor (ASQ CQA), Summer exemplifies the regulatory excellence that drives innovation forward.   Join Summer and other industry leaders as they explore how digital transformation is reshaping regulatory affairs and healthcare delivery.   📅 August 27, 2025 | 5:30-8:00 PM PDT 📍 Vue Research Center, Seattle, WA   Thank you to Women In Bio - Seattle and ORCA for hosting this important industry discussion. https://lnkd.in/gfdHmUmC

"China's rise in biotechnology is no longer a distant possibility — it's here. Last year, Chinese firms accounted for over a third of all Big Pharma acquisitions globally. These companies offer something America's bloated drug development ecosystem increasingly struggles to deliver: speed." How can U.S. drug research maintain its competitive edge? Our CEO Brian Finrow, in collaboration with Sandeep Patel, explores strategic solutions for accelerating American innovation while preserving rigorous safety standards. Read their analysis here, published in STAT. https://lnkd.in/g8Sc6m-d

Our CEO Brian Finrow recently sat down with The Bio Report to discuss how Lumen is revolutionizing biologics production using algae (spirulina). In this episode, Brian shares insights on: - How we're transforming drug manufacturing economics - The potential of our spirulina-based platform technology - Our approach to making biologics more accessible and affordable Listen to the full episode here: https://lnkd.in/gJMaxAnT

Good or bad, when institutions are remade it's an opportunity for fresh new ideas to root. There's already plenty of negative criticism out there—from all sides—but Sandeep Patel and I jotted down some constructive ideas to throw into the mix—published here in STAT. What do you think? https://lnkd.in/ef2GYckm

We recently shared significant results from our early clinical trial results of evaluating LMN-201 in helping treat Clostridioides difficile infection. The results from our sentinel cohort demonstrated: - 100% initial clinical cure (95% c.i.: 85%-100%) - 95.2% sustained cure at 28 days, significantly outperforming previous studies (p<0.001) - Marked reduction in recurrence at 28 days (4.8%) compared to previous studies (26%) These outcomes support the potential of our proprietary spirulina-based platform, which enables oral delivery of biologics with sustainably reduced production costs compared to conventional methods. With C. difficile affecting approximately 500,000 Americans annually and causing an estimated 29,000 deaths each year, LMN-201 represents a promising advancement in addressing this significant medical need. The RePreve Trial main cohort is currently recruiting participants. For additional information about how to partner with us, please visit RePreveStudy.org and www.Lumen.Bio

lumen.bio/careers

Discover how intranasal biologics can reach population scale! Our CEO Brian Finrow will be presenting "Keep It Simple Stupid: Making Intranasal Biologic Drugs for Population Scale Access" at the 3rd Annual Nasal Formulation & Delivery Summit in Boston next week. Register through: https://lnkd.in/gAWg2dtn April 1-3, 2024 | Boston, MA

Join us next Tuesday as our CEO Brian Finrow moderates Life Science Washington's expert panel on moving new drugs into the clinic. March 25, 2025 | 11:30 AM - 1:30 PM | Seattle, WA Register through Life Science Washington:  lifesciencewa.org/events